Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Ramos El"'
Autor:
Robert W. G. Johnson, Ian R. Hardie, Amy Lin, Björn Nashan, Mark D. Pescovitz, Flavio Vincenti, Ginny L. Bumgardner, Ramos El
Publikováno v:
Transplantation. 72:839-845
Background. Daclizumab (Zenapax, Roche Pharmaceuticals), a humanized monoclonal antibody directed against the [alpha] chain of the interleukin 2 receptor, has been shown to reduce the incidence of acute rejection at 6 months after renal transplantati
Publikováno v:
Transplantation. 72:642-647
BACKGROUND The purpose of this retrospective study was to determine the benefits of daclizumab, (Zenapax, Roche Pharmaceuticals) a humanized anti-interleukin-2Ralpha (IL-2Ralpha) monoclonal antibody, for prevention of acute rejection in renal transpl
Publikováno v:
New England Journal of Medicine. 331:358-363
The safety of long-term immunosuppression with cyclosporine in renal-transplant recipients is not well understood. This drug may cause a progressive toxic nephropathy, but it also preserves renal function because it prevents rejection. To determine t
Autor:
Ramos El, M. E. Brunson, Janet L. Karlix, William W. Pfaff, Richard J. Howard, John C. Peterson, Pamela R. Patton
Publikováno v:
Transplantation. 57:889-892
A prospective randomized trial was conducted to compare the effect of diltiazem (DILT) with ketoconazole (KETO) on sparing of cyclosporine dose and renal transplant outcome. Final allograft recipients 18 years old and older were eligible for the stud
Autor:
Ramos El, F Stuart, S. Cho, Bjoern Nashan, Miguel Angel Navarro, Josep M. Grinyó, Henrik Ekberg, Flavio Vincenti, Dirk Kuypers, A Khanna, Christina Brattström, Rachel J. Johnson
Publikováno v:
Transplantation. 71(9)
Background The adoption of calcineurin inhibitors (CNI) as the mainstay of immunosuppression has resuited in a significant decrease of acute rejection and improvement of short-term graft survival. However, because of the irreversible nephrotoxicity a
Autor:
Edgar L. Milford, Charles B. Carpenter, Nicholas L. Tilney, Waldmann Ta, C. E. Zimmerman, Robert L. Kirkman, Terry B. Strom, Michael E. Shapiro, Ramos El, Dianne B. McKay
Publikováno v:
Transplantation. 51(1)
Patient entry is now complete in a prospective trial of anti-Tac, a murine IgG2a monoclonal antibody directed against the p55 chain of the human IL-2 receptor, for the prevention of renal allograft rejection. Recipients of primary cadaver allografts
Publikováno v:
Transplantation. 67:S562
Publikováno v:
Transplantation. 67:S124
Autor:
Donald Potter, Mark D. Pescovitz, Robert B. Ettenger, Thomas E. Nevins, Stuart J. Knechtle, Paul M. Colombani, Steven R. Alexander, Ramos El
Publikováno v:
Transplantation. 67:S124
Autor:
F Stuart, Ramos El, Flavio Vincenti, Y. Vanrenterghem, Rachel J. Johnson, Christina Brattström, J. M. Grinyo, Bjoern Nashan, S. Cho, Henrik Ekberg
Publikováno v:
Transplantation. 65:S190